直肠癌新辅助放化疗后直肠腔内超声T再分期准确性及影响因素  

Accuracy and Influencing Factors of T Restaging by Endorectal Ultrasonography after Neoadjuvant Chemora-diotherapy for Rectal Cancer

作　　者：张瑶 ZHANG Yao(Department of Ultrasound Diagnosis,First Affiliated Hospital of Nanyang Medical College,Nanyang,Henan 473000)

机构地区：[1]南阳医学高等专科学校第一附属医院超声诊断科,河南南阳473000

出　　处：《中国肛肠病杂志》2024年第7期17-19,共3页Chinese Journal of Coloproctology

摘　　要：目的:探讨新辅助放化疗后直肠腔内超声T再分期准确性及影响因素。方法:选取2020-2023年我院收治的60例直肠癌患者为研究参与者,均行新辅助放化疗治疗,治疗后采用直肠腔内超声评估肿瘤T分期,以术后病理诊断T分期为金标准,比较不同年龄、性别、肿瘤位置、复查时间等资料患者直肠腔内超声评估准确率,以组间比较差异显著的资料为自变量进行多因素Logistic回归性分析。结果:60例直肠癌患者新辅助放化疗后直肠腔内超声评估肿瘤T分期准确率为70.0%(42/60)。不同复查时间、肿瘤位置、Wheeler直肠癌消退分级的患者直肠腔内超声T分期评估准确率差异具有统计学意义(P<0.05);不同年龄、性别、是否血管侵犯、淋巴结转移患者准确率差异无统计学意义(P>0.05);Logistic回归性分析显示低位直肠癌、复查时间<6周是直肠腔内超声T再分期准确性的影响因素。结论:直肠癌新辅助放化疗后可通过直肠腔内超声诊断进行初步的T再分期评估,但低位直肠癌、复查时间较短可能影响评估的准确性。Objective To investigate the accuracy and influencing factors of T restaging by endorectal ul-trasonography(ERUS)after neoadjuvant chemoradiotherapy.Methods Sixty patients with rectal cancer admitted to our hospital from 2020 to 2023 were selected as study participants,all of whom received neo-adjuvant chemoradiotherapy.ERUS was used to evaluate tumor T staging after treatment.T staging of postoperative pathological diagnosis was used as the gold standard,and the accuracy rate of ERUS was compared among patients with different age,gender,tumor location,follow-up time and other data.Multi-variate logistic regression analysis was performed by using data with significant differences between groups as independent variables.Results In 60 patients with rectal cancer,the accuracy rate of T staging was 70.0%(42/60)after neoadjuvant chemoradiotherapy.There were significant differences in the accuracy of T staging evaluation of ERUS in patients with different follow-up time,tumor location and Wheeler regres-sion grade(P<0.05).There was no significant difference in the accuracy rate among patients with differ-ent age,gender,vascular invasion or lymph node metastasis(P>0.05).Logistic regression analysis showed that low rectal cancer and follow-up time<6 weeks were influential factors for the accuracy of T restaging of ERUS.Conclusion After neoadjuvant chemoradiotherapy for rectal cancer,a preliminary T-restaging evaluation can be performed by ERUS diagnosis,but the accuracy of evaluation may be influ-enced by low rectal cancer and short follow-up time.

关 键 词：直肠癌 新辅助放化疗 直肠腔内超声 T再分期 准确性 影响因素 

分 类 号：R735.37[医药卫生—肿瘤]